MISSION
Our mission is to improve clinical outcomes for patients with liver cancer by developing new biomarkers and therapies. To achieve this, we conduct basic and translational research to unravel the molecular mechanisms driving tumor recurrence and therapy resistance using cutting-edge technologies.
Just as importantly, we are committed to training the next generation of researchers to advance the future of liver cancer treatment.
VISION
Discover a cure for liver cancer through innovative experimentation.
CORE VALUES
We believe people come first.
We value innovation and creativity.
We strive for excellence with integrity.
NEWS AND EVENTS
R37 Method to Extend Research in Time (MERIT) Award
Renu Dhanasekaran received the MERIT award ti study the "Dysregulated Complement Pathway in Macrophage Reprogramming and Progression of HCC in MASH" from the National Cancer Institute (NCI).
Stanford School of Medicine Dean's Postdoctoral Fellowship
Lea Lemaitre received the competitive fellowship to study the "Evaluating adjuvant therapies to prevent cancer recurrence" from the Stanford School of Medicine.
Translational Research and Applied Medicine (TRAM) Award
Lea Lemaitre mentored by Dhanasekaran received this grant to study "Teaming up against Cancer: Dynamics between macrophages and T cells in Hepatocellular Carcinoma".
ACG Established Investigator Bridge Award
Dhanasekaran received this grant to study the "Molecular Determinants of Hepatocellular Carcinoma Disparities Among Hispanic Patients" from the American College of Gastroenterology (ACG).
AASLD Bridge Funding Award
Dhanasekaran received this grant to study "Disrupting the Sinister Nexus between Macrophages and Stem-like Cancer Cells in Cancer Recurrence from the American Association for the Study of Liver Diseases (AASLD).
Renu Dhanasekaran MD
